Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL ‐2 Inhibitors
Cancer Medicine · 2026
DOI: 10.1002/cam4.72341 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2026. Verfasst von Finn J Schulze und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Agammaglobulinaemia Tyrosine Kinase, Proto-Oncogene Proteins c-bcl-2, Protein Kinase Inhibitors. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Although chronic lymphocytic leukemia (CLL) typically follows an indolent course involving blood, lymph nodes, and bone marrow, extranodal organ involvement is rare and poorly characterized.
Methods
We retrospectively analyzed 19 patients with histologically confirmed extranodal CLL or small lymphocytic lymphoma (SLL), assessing organ involvement, clinical features, genetic risk factors, and response to therapy.
Results
Different organs were affected, most frequently the kidneys (7/19). Median age at initial CLL diagnosis was 54 years, median time from CLL diagnosis to extranodal manifestation was 3 years. Genetic risk factors were comparable to typical CLL cohorts. Per treatment episode, exploratory overall response rate (ORR) for Bruton tyrosine kinase inhibitors (BTKi) was 88.9% (8/9); median progression‐free survival (PFS) from treatment initiation was 29 months. For venetoclax‐based regimens, ORR was 83.3% (5/6) and median PFS 52 months.
Conclusions
These data suggest meaningful activity of BTK and BCL‐2 inhibitors in CLL/SLL with extranodal organ involvement.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Münster, Germany.
- Oncology Practice and Day Clinic, Gelsenkirchen, Germany.
- MVZ Media Vita Münster, Hematology and Oncology Practice, Münster, Germany.
- Department of Hematology and Medical Oncology, University Hospital Göttingen, Göttingen, Germany.
ORCID-Profile: Finn J Schulze, Evgenii Shumilov, Andrea Kerkhoff, Markus Maulhardt, Alexander Pohlmann
Zitieren
APA
Schulze, F. J., Shumilov, E., Behringer, A., Kerkhoff, A., Eckhardt, M., Bätker, S., Maulhardt, M., Lenz, G., & Pohlmann, A. (2026). Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL ‐2 Inhibitors. Cancer Medicine. https://doi.org/10.1002/cam4.72341
Vancouver
Schulze FJ, Shumilov E, Behringer A, Kerkhoff A, Eckhardt M, Bätker S, et al. Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL ‐2 Inhibitors. Cancer Medicine. 2026. doi:10.1002/cam4.72341
BibTeX
@article{Schulze2026,
author = {Schulze, Finn J and Shumilov, Evgenii and Behringer, Akhil and Kerkhoff, Andrea and Eckhardt, Matthias and Bätker, Simone and Maulhardt, Markus and Lenz, Georg and Pohlmann, Alexander},
title = {Extranodal Organ Involvement in Chronic Lymphocytic Leukemia: Clinical Features and Outcomes With Bruton Tyrosine Kinase and BCL ‐2 Inhibitors},
journal = {Cancer Medicine},
year = {2026},
doi = {10.1002/cam4.72341}
}
EUVIMED